FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer

[FDA]

On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm


Baca selengkapnya di : http://www.fda.gov...